{"slug":"chemotherapy","tag":"chemotherapy","variants":["chemotherapy"],"description":"No description yet","count":10,"kinds":{"person":6,"term":4},"related":[{"slug":"rejuvenation","tag":"rejuvenation","shared":4},{"slug":"second-cancers","tag":"second-cancers","shared":4},{"slug":"survivorship","tag":"survivorship","shared":4},{"slug":"blood","tag":"blood","shared":2},{"slug":"eortc","tag":"eortc","shared":2},{"slug":"trialist","tag":"trialist","shared":2},{"slug":"biliary","tag":"biliary","shared":1},{"slug":"bladder","tag":"bladder","shared":1},{"slug":"colorectal","tag":"colorectal","shared":1},{"slug":"cooperative-group","tag":"cooperative-group","shared":1},{"slug":"glioma","tag":"glioma","shared":1},{"slug":"head-and-neck","tag":"head-and-neck","shared":1}],"records":[{"id":"aimery-de-gramont","kind":"person","name":"Aimery de Gramont","route":"/people/aimery-de-gramont/","tldr":"Invented the FOLFOX regimen that anchors colorectal chemotherapy and founded the GERCOR and ARCAD trial groups."},{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","route":"/people/thierry-conroy/","tldr":"Led the FOLFIRINOX trials that gave pancreatic cancer its most active chemotherapy in both metastatic and adjuvant settings."},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","tldr":"Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1."},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","tldr":"Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status."},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/","tldr":"Led EXTREME and TAX 323, which defined the chemotherapy standards for head and neck cancer for a decade."},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/","tldr":"Developed dose-adjusted EPOCH-R, the regimen that cures primary mediastinal B-cell lymphoma without radiotherapy."},{"id":"rejuv-second-alkylating-agents-and-myeloid-neoplasms","kind":"term","name":"Alkylating agents and therapy-related myeloid neoplasms","route":"/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/","tldr":"Alkylating chemotherapy can damage a blood stem cell in a way that shows up years later as myelodysplastic syndrome or acute myeloid leukaemia. It is uncommon, it depends on the total dose, and the risk falls away after about ten years. Knowing the cumulative dose you were given is the single most useful thing on your treatment summary."},{"id":"rejuv-second-topoisomerase-inhibitors-short-latency","kind":"term","name":"Topoisomerase II inhibitors and the shorter latency","route":"/terms/rejuv-second-topoisomerase-inhibitors-short-latency/","tldr":"Etoposide and the anthracyclines can cause a leukaemia too, but a different one: it arrives after about two years rather than six, it starts as acute leukaemia without a myelodysplastic phase, and it carries a balanced break in a chromosome rather than a missing piece. So the first two or three years after this chemotherapy are when a blood count matters most."},{"id":"second-primary-bladder-after-cyclophosphamide","kind":"term","name":"Bladder cancer after cyclophosphamide","route":"/terms/second-primary-bladder-after-cyclophosphamide/","tldr":"Cyclophosphamide is one of the few cancer drugs that has been shown to cause a specific solid cancer, in the bladder, and the risk depends steeply on the total dose given. Blood in the urine years after treatment with it is a reason to be investigated rather than reassured, and the cumulative dose on your treatment summary is what tells you where you sit."},{"id":"rejuv-second-choices-made-at-treatment","kind":"term","name":"Choices made at the time of treatment that change the second cancer risk","route":"/terms/rejuv-second-choices-made-at-treatment/","tldr":"Some of this risk is a decision rather than a fate. Where two treatments cure equally well and one carries less late risk, that is a conversation to have before treatment starts. Trials have settled several: a different partner drug in myeloma, a lower cyclophosphamide dose in breast cancer, brachytherapy rather than external beam."}]}